Squarepoint’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $92.6K | Sell |
66,152
-128,253
| -66% | -$209K | ﹤0.01% | 4214 |
|
|
2026
Q1 | $329K | Buy |
194,405
+101,649
| +110% | +$180K | ﹤0.01% | 3637 |
|
|
2025
Q4 | $132K | Buy |
+92,756
| New | +$135K | ﹤0.01% | 3986 |
|
|
2025
Q3 | – | Sell |
-41,058
| Closed | -$30K | – | 4421 |
|
|
2025
Q2 | $30K | Buy |
+41,058
| New | +$35.4K | ﹤0.01% | 4362 |
|
|
2024
Q3 | – | Sell |
-10,214
| Closed | -$17.7K | – | 4164 |
|
|
2024
Q2 | $17.7K | Sell |
10,214
-57,364
| -85% | -$115K | ﹤0.01% | 3967 |
|
|
2024
Q1 | $162K | Sell |
67,578
-93,547
| -58% | -$230K | ﹤0.01% | 3683 |
|
|
2023
Q4 | $537K | Buy |
+161,125
| New | +$432K | ﹤0.01% | 2958 |
|
|
2023
Q3 | – | Sell |
-285,338
| Closed | -$1.22M | – | 3836 |
|
|
2023
Q2 | $1.22M | Buy |
285,338
+197,489
| +225% | +$1.17M | ﹤0.01% | 2019 |
|
|
2023
Q1 | $601K | Buy |
87,849
+54,284
| +162% | +$421K | ﹤0.01% | 2197 |
|
|
2022
Q4 | $266K | Sell |
33,565
-38,946
| -54% | -$300K | ﹤0.01% | 2633 |
|
|
2022
Q3 | $697K | Buy |
+72,511
| New | +$734K | ﹤0.01% | 2008 |
|
|
2021
Q3 | – | Sell |
-116,257
| Closed | -$1.61M | – | 2963 |
|
|
2021
Q2 | $1.61M | Buy |
+116,257
| New | +$1.65M | 0.01% | 1317 |
|
|
2021
Q1 | – | Sell |
-22,254
| Closed | -$387K | – | 3167 |
|
|
2020
Q4 | $387K | Buy |
+22,254
| New | +$396K | ﹤0.01% | 2019 |
|
|
2020
Q3 | – | Sell |
-16,280
| Closed | -$291K | – | 2511 |
|
|
2020
Q2 | $291K | Sell |
16,280
-90,085
| -85% | -$1.52M | ﹤0.01% | 1621 |
|
|
2020
Q1 | $1.73M | Buy |
106,365
+13,841
| +15% | +$256K | 0.04% | 499 |
|
|
2019
Q4 | $1.67M | Buy |
92,524
+62,683
| +210% | +$1.16M | 0.01% | 1018 |
|
|
2019
Q3 | $605K | Sell |
29,841
-49,732
| -62% | -$994K | 0.01% | 1516 |
|
|
2019
Q2 | $1.76M | Buy |
79,573
+4,184
| +6% | +$72.7K | 0.02% | 919 |
|
|
2019
Q1 | $1.03M | Buy |
+75,389
| New | +$1.01M | 0.01% | 1097 |
|
|
2018
Q4 | – | Sell |
-20,780
| Closed | -$343K | – | 1966 |
|
|
2018
Q3 | $343K | Buy |
+20,780
| New | +$368K | ﹤0.01% | 1470 |
|
|
2018
Q1 | – | Sell |
-23,032
| Closed | -$203K | – | 1734 |
|
|
2017
Q4 | $203K | Buy |
23,032
+6,740
| +41% | +$72.2K | ﹤0.01% | 1786 |
|
|
2017
Q3 | $217K | Sell |
16,292
-47,278
| -74% | -$625K | ﹤0.01% | 1345 |
|
|
2017
Q2 | $912K | Buy |
63,570
+53,711
| +545% | +$1.03M | 0.02% | 759 |
|
|
2017
Q1 | $209K | Buy |
+9,859
| New | +$243K | 0.01% | 1268 |
|
|
2016
Q1 | – | Sell |
-10,700
| Closed | -$246K | – | 1200 |
|
|
2015
Q4 | $246K | Buy |
+10,700
| New | +$275K | 0.03% | 895 |
|
Other funds holding CHRS
TGY2IT
SB
KKRC
CM
CWG
Squarepoint's CHRS Position: Q2 2026 in Review
Squarepoint reduced its Coherus Oncology (CHRS) stake by 66% in Q2 2026, selling an estimated $209K and leaving 66,152 shares worth $92.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4214.
Squarepoint first reported a position in CHRS in Q4 2015 and has held it in 25 quarters since. The position peaked at $1.76M in Q2 2019. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.
- Squarepoint held 66,152 shares of Coherus Oncology worth $92.6K as of Q2 2026.
- Squarepoint sold 128,253 Coherus Oncology shares in Q2 2026, an estimated $209K.
- Coherus Oncology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4214 holding.
- Squarepoint first reported a position in Coherus Oncology in Q4 2015 and has held it in 25 quarters since.
- Squarepoint's Coherus Oncology position peaked at $1.76M in Q2 2019.
- 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.